Polyneuron

OverviewSuggest Edit

Polyneuron is a pharmaceutical company that is committed to the development of a new drug class for the treatment of antibody-mediated autoimmune diseases of the nervous system where a pathological role of anti-carbohydrate autoantibodies is well established. The Company’s Antibody-Catch™ technology platform enables the chemical design of injectable glycopolymers that are able to selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact.

TypePrivate
Founded2014
HQBasel, CHMap
Websitepolyneuron.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jan 2021)16
Cybersecurity ratingBMore

Key People/Management at Polyneuron

Ruben Herrendorff

Ruben Herrendorff

Co-Founder & CEO
Pascal Haenggi

Pascal Haenggi

Co-Founder & CSO
Michael Wacker

Michael Wacker

CBO
Show more

Polyneuron Office Locations

Polyneuron has an office in Basel
Basel, CH (HQ)
Hochbergerstrasse 60C
Show all (1)

Polyneuron Financials and Metrics

Summary Metrics

Founding Date

2014

Polyneuron total Funding

$44.3 m

Polyneuron latest funding size

$15.33 m

Time since last funding

4 months ago

Polyneuron investors

New Enterprise Associates, Sofinnova Partners, EVA Basel, Zürcher Kantonal Bank, HBM Healthcare Investments, Venture Kick
Polyneuron's latest funding round in September 2020 was reported to be $15.3 m. In total, Polyneuron has raised $44.3 m
Show all financial metrics

Polyneuron Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

Learn more about our premium products
SecurityScorecard logo

Polyneuron Online and Social Media Presence

Polyneuron's Trends

Embed Graph

Polyneuron Blogs

October 07, 2020

Polyneuron appoints Aled Williams as chief business officer

We are extremely pleased to welcome Aled Williams to Polyneuron as our new Chief Business Officer. Aled brings more than 25 years’ of leadership experience across both pharmaceutical and biotech sectors. Press Release
September 16, 2020

Polyneuron extends Series A to CHF 36.5 million

Polyneuron announces a CHF 14 million extension of the Series A, bringing the total to CHF 36.5 million. HBM Healthcare Investments has joined the consortium of investors in the Series A, led by Sofinnova Partners, and which included New Enterprise Associates (NEA) and other private investors. Press…
June 05, 2020

Polyneuron’s PN-1007 Receives U.S. FDA Orphan Drug Designation in Anti-MAG Neuropathy

Polyneuron is proud to announce that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN‑1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of…
April 07, 2020

Polyneuron announces appointment of chief medical officer

We are extremely pleased to welcome Dr Debra Barker to Polyneuron as our new chief medical officer. Dr Barker has a successful track record in drug development spanning over 25 years, involving many successful drug approvals. Press Release

 Polyneuron Frequently Asked Questions

  • When was Polyneuron founded?

    Polyneuron was founded in 2014.

  • Who are Polyneuron key executives?

    Polyneuron's key executives are Ruben Herrendorff, Pascal Haenggi and Michael Wacker.

  • How many employees does Polyneuron have?

    Polyneuron has 16 employees.

  • Who are Polyneuron competitors?

    Competitors of Polyneuron include ReViral, Sosei Heptares and Seres Therapeutics.

  • Where is Polyneuron headquarters?

    Polyneuron headquarters is located at Hochbergerstrasse 60C, Basel.

  • Where are Polyneuron offices?

    Polyneuron has an office in Basel.

  • How many offices does Polyneuron have?

    Polyneuron has 1 office.